443 related articles for article (PubMed ID: 24680062)
1. FTY720 impairs CD8 T-cell function independently of the sphingosine-1-phosphate pathway.
Ntranos A; Hall O; Robinson DP; Grishkan IV; Schott JT; Tosi DM; Klein SL; Calabresi PA; Gocke AR
J Neuroimmunol; 2014 May; 270(1-2):13-21. PubMed ID: 24680062
[TBL] [Abstract][Full Text] [Related]
2. Fingolimod targeting protein phosphatase 2A differently affects IL-33 induced IL-2 and IFN-γ production in CD8(+) lymphocytes.
Ottenlinger F; Schwiebs A; Pfarr K; Wagner A; Grüner S; Mayer CA; Pfeilschifter JM; Radeke HH
Eur J Immunol; 2016 Apr; 46(4):941-51. PubMed ID: 26683421
[TBL] [Abstract][Full Text] [Related]
3. Modulation of T cell homeostasis and alloreactivity under continuous FTY720 exposure.
Metzler B; Gfeller P; Wieczorek G; Li J; Nuesslein-Hildesheim B; Katopodis A; Mueller M; Brinkmann V
Int Immunol; 2008 May; 20(5):633-44. PubMed ID: 18343890
[TBL] [Abstract][Full Text] [Related]
4. Novel oxazolo-oxazole derivatives of FTY720 reduce endothelial cell permeability, immune cell chemotaxis and symptoms of experimental autoimmune encephalomyelitis in mice.
Imeri F; Fallegger D; Zivkovic A; Schwalm S; Enzmann G; Blankenbach K; Meyer zu Heringdorf D; Homann T; Kleuser B; Pfeilschifter J; Engelhardt B; Stark H; Huwiler A
Neuropharmacology; 2014 Oct; 85():314-27. PubMed ID: 24863045
[TBL] [Abstract][Full Text] [Related]
5. FTY720 preferentially depletes naive T cells from peripheral and lymphoid organs.
Hofmann M; Brinkmann V; Zerwes HG
Int Immunopharmacol; 2006 Dec; 6(13-14):1902-10. PubMed ID: 17161343
[TBL] [Abstract][Full Text] [Related]
6. FTY720, sphingosine 1-phosphate receptor modulator, ameliorates experimental autoimmune encephalomyelitis by inhibition of T cell infiltration.
Kataoka H; Sugahara K; Shimano K; Teshima K; Koyama M; Fukunari A; Chiba K
Cell Mol Immunol; 2005 Dec; 2(6):439-48. PubMed ID: 16426494
[TBL] [Abstract][Full Text] [Related]
7. Fingolimod (FTY720), sphingosine 1-phosphate receptor modulator, shows superior efficacy as compared with interferon-β in mouse experimental autoimmune encephalomyelitis.
Chiba K; Kataoka H; Seki N; Shimano K; Koyama M; Fukunari A; Sugahara K; Sugita T
Int Immunopharmacol; 2011 Mar; 11(3):366-72. PubMed ID: 20955831
[TBL] [Abstract][Full Text] [Related]
8. Impact of sphingosine 1-phosphate modulation on immune outcomes.
Pinschewer DD; Brinkmann V; Merkler D
Neurology; 2011 Feb; 76(8 Suppl 3):S15-9. PubMed ID: 21339486
[TBL] [Abstract][Full Text] [Related]
9. FTY720 ameliorates MOG-induced experimental autoimmune encephalomyelitis by suppressing both cellular and humoral immune responses.
Papadopoulos D; Rundle J; Patel R; Marshall I; Stretton J; Eaton R; Richardson JC; Gonzalez MI; Philpott KL; Reynolds R
J Neurosci Res; 2010 Feb; 88(2):346-59. PubMed ID: 19658199
[TBL] [Abstract][Full Text] [Related]
10. FTY720 (fingolimod) efficacy in an animal model of multiple sclerosis requires astrocyte sphingosine 1-phosphate receptor 1 (S1P1) modulation.
Choi JW; Gardell SE; Herr DR; Rivera R; Lee CW; Noguchi K; Teo ST; Yung YC; Lu M; Kennedy G; Chun J
Proc Natl Acad Sci U S A; 2011 Jan; 108(2):751-6. PubMed ID: 21177428
[TBL] [Abstract][Full Text] [Related]
11. Distinct properties of circulating CD8+ T cells in FTY720-treated patients with multiple sclerosis.
Johnson TA; Lapierre Y; Bar-Or A; Antel JP
Arch Neurol; 2010 Dec; 67(12):1449-55. PubMed ID: 21149809
[TBL] [Abstract][Full Text] [Related]
12. FTY720 (fingolimod) in Multiple Sclerosis: therapeutic effects in the immune and the central nervous system.
Brinkmann V
Br J Pharmacol; 2009 Nov; 158(5):1173-82. PubMed ID: 19814729
[TBL] [Abstract][Full Text] [Related]
13. The sphingosine 1-phosphate receptor agonist FTY720 differentially affects the sequestration of CD4+/CD25+ T-regulatory cells and enhances their functional activity.
Sawicka E; Dubois G; Jarai G; Edwards M; Thomas M; Nicholls A; Albert R; Newson C; Brinkmann V; Walker C
J Immunol; 2005 Dec; 175(12):7973-80. PubMed ID: 16339533
[TBL] [Abstract][Full Text] [Related]
14. FTY720 therapy exerts differential effects on T cell subsets in multiple sclerosis.
Mehling M; Brinkmann V; Antel J; Bar-Or A; Goebels N; Vedrine C; Kristofic C; Kuhle J; Lindberg RL; Kappos L
Neurology; 2008 Oct; 71(16):1261-7. PubMed ID: 18852441
[TBL] [Abstract][Full Text] [Related]
15. FTY720 stimulates multidrug transporter- and cysteinyl leukotriene-dependent T cell chemotaxis to lymph nodes.
Honig SM; Fu S; Mao X; Yopp A; Gunn MD; Randolph GJ; Bromberg JS
J Clin Invest; 2003 Mar; 111(5):627-37. PubMed ID: 12618517
[TBL] [Abstract][Full Text] [Related]
16. [Fingolimod therapy in multiple sclerosis--the issue of the pathomechanism].
Tar L; Vécsei L
Ideggyogy Sz; 2012 Mar; 65(3-4):83-100. PubMed ID: 23136726
[TBL] [Abstract][Full Text] [Related]
17. Cbl-b-deficient mice express alterations in trafficking-related molecules but retain sensitivity to the multiple sclerosis therapeutic agent, FTY720.
Fujiwara M; Anstadt EJ; Khanna KM; Clark RB
Clin Immunol; 2015 May; 158(1):103-13. PubMed ID: 25829233
[TBL] [Abstract][Full Text] [Related]
18. FTY720, a synthetic sphingosine 1 phosphate analogue, inhibits development of atherosclerosis in low-density lipoprotein receptor-deficient mice.
Nofer JR; Bot M; Brodde M; Taylor PJ; Salm P; Brinkmann V; van Berkel T; Assmann G; Biessen EA
Circulation; 2007 Jan; 115(4):501-8. PubMed ID: 17242282
[TBL] [Abstract][Full Text] [Related]
19. FTY720 (fingolimod) modulates the severity of viral-induced encephalomyelitis and demyelination.
Blanc CA; Rosen H; Lane TE
J Neuroinflammation; 2014 Aug; 11():138. PubMed ID: 25138356
[TBL] [Abstract][Full Text] [Related]
20. Effect of sphingosine 1-phosphate (S1P) receptor agonists FTY720 and CYM5442 on atherosclerosis development in LDL receptor deficient (LDL-R⁻/⁻) mice.
Poti F; Costa S; Bergonzini V; Galletti M; Pignatti E; Weber C; Simoni M; Nofer JR
Vascul Pharmacol; 2012 Aug; 57(1):56-64. PubMed ID: 22459073
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
